 |
Generic Name: Eribulin
Brand Name(s): HALAVEN®
IUPAC: 11,15:18,21:24,28 Triepoxy-7,9-ethano-12,15-methano-9H,15H-furo[3,2-i]furo[2',3':5,6]pyrano[4,3 b][1,4]dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2-hydroxypropyl]hexacosahydro-3 methoxy-26-methyl-20,27-bis(methylene)-, (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-, methanesulfonate (salt)
FDA Approval: yes
Manufacturer Link
|
Usage: Eribulin mesylate (Halaven®) was approved in November 2010 for the treatment of
metastatic breast cancer that has been previously treated with at least one
taxane and one anthracyline
chemotherapy drug. The drug is given via an intravenous (IV) injection.
Mechanism: Eribulin mesylate is a man-made drug derived from a chemical obtained from a sea sponge. The drug binds to the
protein tubulin and prevents it from forming polymers. This prevents the formation of the bundle of microtubules (spindle) that is needed for cells to divide. Other drugs that work by blocking
microtubule formation include the vinca alkaloids, vinblastine and vinorelbine.
Side Effects: Side effects of this drug may include nausea, stomach problems, constipation, tiredness (fatigue), hair loss, decreased white blood counts (neutropenia) and pain or numbness of the hands and feet (peripheral neuropathy). The drug can lead to an abnormal heart beat. Like any drug that causes decreases in white blood counts, risk of infection may be increased.
Contraindications: Eribulin mesylate should not be used by pregnant women or women who could become pregnant. Women using the drug can not breastfeed. Patients with kidney, liver or heart disease should discuss this with their healthcare provider.
Print
Email Page
